Castle Biosciences President and CEO Derek J. Maetzold Reports Sale of $523,329.668 in Common Shares
Bitget2026/11/04 21:09- Castle Biosciences President and CEO Derek J. Maetzold sold 14,496 common shares on Nov. 2, 2026.
- Sales comprised 12,764 shares at $36.005 per share and 1,732 shares at $36.814 per share.
- Following the transactions, Maetzold held 3,904 shares directly and 152,038 shares indirectly through trusts.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AppLovin (APP.US) delivers "textbook-level" performance: Q3 revenue surges 55%, net profit margin of 66% tops the advertising industry! $1.4 billion buyback in a single quarter
AppLovin (APP.US) released its financial results for the third quarter of 2026 (ending September 30) after the US stock market closed on Wednesday. The advertising technology company once again delivered a "textbook-level" performance: revenue, net profit, and adjusted EBITDA all reached record highs for a single quarter, with profitability indicators far ahead of major advertising platforms.
BUZZ - Edwards Lifesciences shares rise after raising 2026 profit outlook
Crypto prices
More
